A Cost-Effectiveness Analysis of Axitinib and Sorafenib for 2nd Line Treatment of Advanced Renal Cell Carcinoma After Failure of Cytokines in the United States
Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.500
https://www.valueinhealthjournal.com/article/S1098-3015(13)02405-4/fulltext
Title :
A Cost-Effectiveness Analysis of Axitinib and Sorafenib for 2nd Line Treatment of Advanced Renal Cell Carcinoma After Failure of Cytokines in the United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)02405-4&doi=10.1016/j.jval.2013.08.500
First page :
A410
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
482